Stockscreener 앱 받기
18.27
3.64%
-0.69
시간 외 거래:
18.34
0.07
+0.38%
전일 마감가:
$18.96
열려 있는:
$18.83
하루 거래량:
2.98M
Relative Volume:
1.32
시가총액:
$3.37B
수익:
$797.73M
순이익/손실:
$-325.77M
주가수익비율:
-10.31
EPS:
-1.7725
순현금흐름:
$-332.79M
1주 성능:
-21.99%
1개월 성능:
-18.91%
6개월 성능:
-57.86%
1년 성능:
-50.14%
1일 변동 폭
$18.23
$19.28
1주일 범위
$18.23
$22.04
52주 변동 폭
$18.23
$44.90
Legend Biotech Corp Adr Stock (LEGN) Company Profile
LEGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
18.27 | 3.50B | 797.73M | -325.77M | -332.79M | -1.7725 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-22 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2026-01-07 | 개시 | Oppenheimer | Outperform |
| 2025-10-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-06-17 | 개시 | Truist | Buy |
| 2024-05-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-05-23 | 개시 | Deutsche Bank | Buy |
| 2024-04-17 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | Raymond James | Outperform |
| 2023-12-19 | 개시 | Scotiabank | Sector Perform |
| 2023-11-06 | 개시 | Goldman | Buy |
| 2023-05-25 | 개시 | William Blair | Mkt Perform |
| 2023-05-22 | 개시 | Daiwa Securities | Buy |
| 2023-03-29 | 개시 | H.C. Wainwright | Buy |
| 2023-03-24 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-11-02 | 개시 | Evercore ISI | Outperform |
| 2022-11-01 | 개시 | Cowen | Outperform |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-03-15 | 개시 | Barclays | Overweight |
| 2022-01-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2020-07-01 | 개시 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Morgan Stanley | Overweight |
모두보기
Legend Biotech Corp Adr 주식(LEGN)의 최신 뉴스
Legend Biotech (NASDAQ:LEGN) Hits New 12-Month LowTime to Sell? - MarketBeat
Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline - Finviz
Legend Biotech FY2025 EPS Estimate Lifted by HC Wainwright - MarketBeat
Legend Biotech (NASDAQ:LEGN) Price Target Lowered to $50.00 at HC Wainwright - Defense World
Legend Biotech (NASDAQ:LEGN) Shares Gap Down on Analyst Downgrade - Defense World
H.C. Wainwright lowers Legend Biotech stock price target on Q4 sales miss By Investing.com - Investing.com South Africa
H.C. Wainwright lowers Legend Biotech stock price target on Q4 sales miss - Investing.com
Rakuten Investment Management Inc. Takes $7.58 Million Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech stock rating downgraded by TD Cowen on Carvykti concerns - Investing.com South Africa
Legend Biotech (NASDAQ:LEGN) Hits New 52-Week LowHere's Why - MarketBeat
Legend Biotech stock hits 52-week low at $20.15 - Investing.com
Legend Biotech (NASDAQ:LEGN) Given “Outperform” Rating at Royal Bank Of Canada - Defense World
Raymond James reiterates Outperform rating on Legend Biotech stock By Investing.com - Investing.com India
Raymond James reiterates Outperform rating on Legend Biotech stock - Investing.com
Legend Biotech stock rises as FDA draft guidance supports accelerated approval endpoints By Investing.com - Investing.com South Africa
Legend Biotech stock rises as FDA draft guidance supports accelerated approval endpoints - Investing.com
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Algonquin Power & Utilities Corp. (NYSE:AQN) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Diana Shipping inc. (NYSE:DSX) Short Interest Update - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Short Interest Up 23.3% in December - MarketBeat
Deutsche Bank reiterates Buy rating on Legend Biotech stock with $60 target - Investing.com
LEGN: CARVYKTI's rapid growth, clinical leadership, and pipeline innovation drive 2026 profitability goals - TradingView — Track All Markets
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN) - Finviz
Legend Biotech (NASDAQ:LEGN) Coverage Initiated by Analysts at Oppenheimer - Defense World
Legend Biotech (NASDAQ:LEGN) Trading Up 7.3%What's Next? - MarketBeat
Legend Biotech (NASDAQ:LEGN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Legend Biotech stock hits 52-week low at 21.16 USD - Investing.com
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Matthews International Capital Management LLC - MarketBeat
Connective Portfolio Management LLC Acquires New Holdings in Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Legend Biotech (LEGN) – Investment Analysts’ Recent Ratings Changes - Defense World
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - The Motley Fool
Here is Why Legend Biotech (LEGN) Offers Such Promising Upside - Finviz
Legend Biotech stock remains Overweight at Cantor Fitzgerald despite YTD decline By Investing.com - Investing.com South Africa
Legend Biotech stock remains Overweight at Cantor Fitzgerald despite YTD decline - Investing.com India
Legend Biotech (NASDAQ:LEGN) Reaches New 52-Week LowWhat's Next? - MarketBeat
Legend Biotech stock hits 52-week low at $22.27 - Investing.com
Squarepoint Ops LLC Grows Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Braidwell LP - MarketBeat
Jump Financial LLC Increases Stake in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Corporation (LEGN) is an Outperform on Multiple Myeloma Treatment CARVYKTI Prospects - Finviz
Nothing is Better Than Harrow Inc (HROW) stock at the moment - Setenews
Ready to Jump After Recent Trade: Venture Global Inc (VG) - setenews.com
Stempoint Capital LP Takes $9.59 Million Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech stock remains Outperform at RBC despite competitive threats By Investing.com - Investing.com South Africa
Legend Biotech (NASDAQ:LEGN) Trading Down 4.7%Time to Sell? - MarketBeat
Legend Biotech stock remains Outperform at RBC despite competitive threats - Investing.com
Federated Hermes Inc. Has $37.75 Million Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech (NASDAQ:LEGN) Sets New 12-Month LowWhat's Next? - MarketBeat
Legend Biotech stock hits 52-week low at $25.66 By Investing.com - Investing.com South Africa
Legend Biotech Corp Adr (LEGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):